Hospital microbiology laboratories from 41 states participated in a bacterial antimicrobial
susceptibility study comparing in vitro results generated by the standardized disk diffusion …

(1) Background: Piperacillin-tazobactam represents the first-line option for treating infections
caused by full-or multi-susceptible Enterobacterales and/or Pseudomonas aeruginosa in …

The pharmacokinetics of piperacillin-tazobactam were investigated in eight anuric intensive
care patients treated by continuous venovenous hemodialysis (CVVHD). The elimination …

Tazobactam (YTR-830H), a novel beta-lactamase inhibitor, was compared with clavulanic
acid and sulbactam for enhancement of the activity of piperacillin against beta-lactamase …

Current data are summarized on the comparative susceptibility of Gram-positive and Gram-
negative anaerobic bacteria to piperacillin/tazobactam and other anti-anaerobe agents. For …

Piperacillin in combination with tazobactam is one of the most commonly used intravenous
antibiotics. There is evidence for a possible saturable elimination of piperacillin. Therefore …

Background: Sustained low-efficiency dialysis (SLED), is increasingly being used in
intensive care units (ICUs) but studies informing drug dosing for such patients is lacking …

An improved HPLC method was developed for the determination of piperacillin and
tazobactam in human plasma and pharmacokinetic study in Chinese healthy volunteers …

The comparative activities of piperacillin/tazobactam and other antibiotics against 5625
Gram-negative and Gram-positive bactena freshly isolated from hospitalized patients was …

The pharmacokinetics of piperacillin, tazobactam and its M1 metabolite were studied in
patients with various degrees of renal impairment after single and multiple intravenous …